Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Analysis of Antihypertensive Treatment Efficacy (ATACA)

This study has been terminated.
Information provided by:
AstraZeneca Identifier:
First received: October 6, 2008
Last updated: December 2, 2010
Last verified: December 2010
Analysis of antihypertensive treatment efficacy.

Arterial Hypertension

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Analysis of Antihypertensive Treatment Efficacy

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Analysis of antihypertensive treatment efficacy. [ Time Frame: measurement BP: 3 visits for 3 month ] [ Designated as safety issue: No ]

Estimated Enrollment: 2000
Study Start Date: May 2008
Study Completion Date: February 2009
Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Male or female with arterial hypertension


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
outpatient clinics

Inclusion Criteria:

  • arterial hypertension
  • intake of Atacand before study enrollment

Exclusion Criteria:

  • hypersensitivity to candesartan or any other ingredient of Atacand
  • liver function impairment and/or cholestasis
  • severe renal insufficiency (serum creatinine > 265 µmol/L)
  • Pregnant and lactating women
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00767247

Russian Federation
Research Site
Arhangelsk, Russian Federation
Research Site
Bryansk, Russian Federation
Research Site
Domodedovo, Russian Federation
Research Site
Dzerzhinsk, Russian Federation
Research Site
Ekaterinburg, Russian Federation
Research Site
Essentuki, Russian Federation
Research Site
Georgievsk, Russian Federation
Research Site
Irkutsk, Russian Federation
Research Site
Kazan, Russian Federation
Research Site
Samara, Russian Federation
Research Site
Severodvinsk, Russian Federation
Research Site
Vidnoe, Russian Federation
Research Site
Volgograd, Russian Federation
Sponsors and Collaborators
Principal Investigator: Dmitry Zateyshchikov, MD, Prof Federal State Institution of Russian President's General Management Department
  More Information

Responsible Party: Andrey Strugovshchikov, Medical Director, Astra Zeneca, Russia Identifier: NCT00767247     History of Changes
Other Study ID Numbers: NIS-CRU-ATA-2008/1 
Study First Received: October 6, 2008
Last Updated: December 2, 2010
Health Authority: Russia: Ethics Committee
Russia: Ministry of Health of the Russian Federation

Keywords provided by AstraZeneca:
Arterial Hypertension

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases
Antihypertensive Agents processed this record on October 28, 2016